SoylentNews is people
SoylentNews
Submitted via IRC for SoyCow1984
Drug companies are sitting on generics—43% of recently approved aren't for sale
Of the more than 1,600 generic drugs approved by the Food and Drug Administration since January of 2017, more than 700—or 43 percent—are not for sale in the US, according to a new analysis by Kaiser Health News.
The finding means that many pricy, brand-name drugs are not facing the competition that could help drive down soaring prices. Among the drugs missing in action are generic versions of the expensive blood thinner Brilinta and the HIV medication Truvada. Moreover, of the approved drugs that would offer a brand-name drug its first competition, 36 percent are being held off the market, the analysis found.
This discussion has been archived.
No new comments can be posted.
Drug Companies are Sitting on Generics—43% of Recently Approved Aren’t for Sale
|
Log In/Create an Account
| Top
| 48 comments
| Search Discussion
The Fine Print: The following comments are owned by whoever posted them. We are not responsible for them in any way.
Q: Why did Menachem Begin invade Lebanon?
A: To impress Jodie Foster.
(Score: 1, Interesting) by Anonymous Coward on Sunday February 10 2019, @02:28PM (2 children)
“Then there’s potentially anti-competitive deals, in which brand-name drug makers simply pay generic makers to keep their product off the market for a while—a so-called “pay for delay” tactic.”
Price collusion or something like that?
(Score: 5, Interesting) by bzipitidoo on Sunday February 10 2019, @06:15PM (1 child)
Oh yes, highly illegal, and unethical, and immoral. But the medical industry abuses the high esteem the public has for medicine to get away with price gouging, price fixing, kickbacks, bribery, and other corrupt and monopolistic practices that would never fly in any other industry.
(Score: 3, Informative) by coolgopher on Monday February 11 2019, @12:22AM
Oh I dunno. Down here both banking and utilities would have a shot at that title.